ODI Pharma, a prominent player in the European medical cannabis market, has reported an impressive financial performance for the third quarter of the 2026 fiscal year. The company has achieved record sales levels, with net sales amounting to SEK 12,712,029, a substantial increase from the previous year's SEK 2,934,337. This marks a significant milestone in the company's history, as year-to-date sales have already surpassed any previous full fiscal year.

The company's profit after financial items also saw a remarkable turnaround, reaching SEK 126,614, compared to a loss of SEK 340,612 in the same period last year. This positive shift is reflected in the result per share, which improved to SEK 0.01 from a negative SEK 0.02.

Over the nine-month period from July 2025 to March 2026, ODI Pharma's net sales totaled SEK 29,753,825, a dramatic increase from SEK 3,064,896 in the previous year. The profit after financial items improved significantly to SEK 1,417,177, compared to a loss of SEK 4,153,493, with the result per share increasing to SEK 0.08 from a negative SEK 0.26. The company's solidity also improved to 17% from 11%, indicating a stronger financial position.

Chairman Volker Wiederrich attributes this growth to a more stable market environment and improved operating conditions. ODI Pharma's commitment to providing high-quality medical cannabis products at competitive prices, particularly in the Polish market, has been instrumental in driving this growth. The company's strategic partnerships and focus on innovation in medical applications further bolster its competitive edge.

Given the company's robust financial performance and strategic positioning in the growing European medical cannabis market, ODI Pharma appears well poised for continued growth. Investors may find the stock attractive for its potential to deliver long-term value.